Quick Answer
Pharmagreen Biotech Inc. reported Stockholders Equity of -$1.82 million for the year ending 2022.
- Pharmagreen Biotech Inc. showed a decrease of -7.7% in Stockholders Equity from 2021 to 2022.
- This data is from Pharmagreen Biotech Inc.'s annual report (Form 10-K), filed with the SEC on January 17, 2023.
- XBRL data for this metric is available from 2018 to 2022 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: -$722.0 thousand | Q4 2019: -$1.05 million | Q1 2020: -$1.00 million | Q2 2020: -$2.24 million | Q4 2020: -$1.75 million | Q1 2021: -$1.87 million | Q2 2021: -$1.84 million | Q4 2021: -$1.58 million | Q1 2022: -$2.40 million | Q2 2022: -$1.89 million | Q3 2022: -$1.78 million | Q4 2022: -$1.75 million | Q1 2023: -$1.94 million | Q2 2023: -$2.10 million.
- Over the full 5 years of available data (2018 to 2022), Pharmagreen Biotech Inc.'s Stockholders Equity has declined by 31.4%.
- Historical annual values: Fiscal year 2022: -$1.82 million | Fiscal year 2021: -$1.69 million | Fiscal year 2020: -$2.93 million | Fiscal year 2019: -$834.5 thousand | Fiscal year 2018: -$1.39 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: